Myostatin / activin-pathway inhibitors (non-bimagrumab)
Muscle & Strength · Myostatin/activin blockade
Tier C
What this is
WADA coverage: activin A-neutralizing antibodies, activin receptor IIB competitors, decoy activin receptors, ACE-031, anti-activin receptor IIB antibodies, myostatin inhibitors, agents reducing or ablating myostatin expression, myostatin-binding proteins, follistatin, myostatin propeptide, myostatin- or precursor-neutralizing antibodies, apitegromab, domagrozumab, landogrozumab and stamulumab. Bimagrumab remains its own row. Additional WADA alias coverage: luspatercept and sotatercept are TGF-beta/activin-family ligand traps listed by WADA under related growth-factor modulation.
Mechanism
Blocking myostatin or activin receptor signaling can increase lean mass in some clinical contexts; functional improvements are much less consistent than muscle-volume changes.
Dose & route
Trial dosing varies widely by biologic; no approved enhancement dose
Citations
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.